We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Yolk, also known as In One Basket Limited, is a pioneering company revolutionizing the food and coffee experience for people on the move. They provide high-quality sandwiches, salads, and improved breakfast options without the premium cost, boasting five successful locations in London and three upcoming openings in the second half of 2023
days to go: TBC investment: Withheld
A craft soft drinks brand bursting with flavour, low in sugar and a healthy, natural choice. GUNNA currently has 4 unique flavours available in cans with over 500,000 units sold across more than 2000 independent retailers. GUNNA has won two esteemed Zenith Global Innovations awards and has increased revenue by 300% compared to 2017.
days to go: Expired investment: £819,150
Positivitea is a range of teas based on the chakras. They are already stocked in over 80 locations throughout the UK and Europe including Urban Outfitters and Fenwick. The use of the proceeds raised will go towards expanding the team and getting Positivitea in more retail outlets and being used by more suppliers.
days to go: Expired investment: £103,640
Q Doctor aims at changing the NHS care delivery with the help of video consulting to benefit patients and clinicians. The company is focusing on delivering a model that keeps modernised NHS care free of charge for the patients. The video solution plugs NHS clinicians to the existing NHS infrastructure and allows them to connect to the NHS patients digitally. With the proceeds, Q Doctor will fulfil its strategy for 2020. It will deploy the funds into labour, development, operations, marketing, and contingency funds.

Pitch Rated

51%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £1,386,200
niix is a fitness app plugging the gap in the market for women approaching 40. Since its launch in 2018, the company has created a 4+ star rated app with more than 1800 paid subscriptions across 25 countries including the US, Canada, and Australia. It also has an online following of tens of thousands. The global fitness app market is growing fast set to be worth $2 billion by 2023 with a focus on weight loss and body aesthetics for millennial markets. niix sees a huge opportunity in this space to support women who have simply outgrown an approach that want the perfect body and be fit lifelong. With the investment, the company will scale up proven marketing channels to grow community and subscriber bases, making niix the no.1 digital fitness brand for women approaching 40+.

Pitch Rated

72%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £153,441
Beef & Brew are a casual steak restaurant looking to expand. They are passionate about what they do, focusing on quality yet affordability by cooking steaks over charcoal, and making classic cocktails yet not charging the earth. Beef & Brew only use great food, sourced from artisan butchers, breweries and vineyards.
days to go: Expired investment: £266,133
BANG! Curry offers a variety of easy, quick and healthy, scratch-cooking products. It joins the ‘home cooking’ community with authentic curry meals, quickly and easily. It is operating in the UK market where 89% of people eat world cuisines. The company has acquired a brand with a small team, with listings in Morrisons, Wholefoods Market and Lakeland. It has a growing online community of over 8,500 and has sold over 100,000 products. The funds will be used on forming a sales team to accelerate growth, increase the UK and global marketing. The investment will also be focused on the working capital to support growth.
days to go: Expired investment: £183,610
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph